Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins.
about
Immune and non-immune responses to hepatitis C virus infectionNeutralizing antibody response to hepatitis C virusIdentification of a novel drug lead that inhibits HCV infection and cell-to-cell transmission by targeting the HCV E2 glycoproteinStructural evidence for a bifurcated mode of action in the antibody-mediated neutralization of hepatitis C virusDiscrete conformations of epitope II on the hepatitis C virus E2 protein for antibody-mediated neutralization and nonneutralizationA hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humansCapitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine designOptimization of peptide arrays for studying antibodies to hepatitis C virus continuous epitopes.Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses.Hepatitis C virus hypervariable region 1 variants presented on hepatitis B virus capsid-like particles induce cross-neutralizing antibodies.A weak neutralizing antibody response to hepatitis C virus envelope glycoprotein enhances virus infectionFine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex.Designing and Development of a DNA Vaccine Based On Structural Proteins of Hepatitis C VirusInduction of broadly neutralising HCV antibodies in mice by integration-deficient lentiviral vector-based pseudotyped particlesWill there be a vaccine to prevent HCV infection?Antigenic cooperation among intrahost HCV variants organized into a complex network of cross-immunoreactivity.Hepatitis C virus infection: establishment of chronicity and liver disease progressionStructure of Hepatitis C Virus Envelope Glycoprotein E1 Antigenic Site 314-324 in Complex with Antibody IGH526.Immunoglobulin with High-Titer In Vitro Cross-Neutralizing Hepatitis C Virus Antibodies Passively Protects Chimpanzees from Homologous, but Not Heterologous, ChallengeBroadly neutralizing immune responses against hepatitis C virus induced by vectored measles viruses and a recombinant envelope protein boosterAntibodies to an interfering epitope in hepatitis C virus E2 can mask vaccine-induced neutralizing activityHepatitis C virus suppresses C9 complement synthesis and impairs membrane attack complex function.The novel replication-defective vaccinia virus (Tiantan strain)-based hepatitis C virus vaccine induces robust immunity in macaquesMapping the genomic diversity of HCV subtypes 1a and 1b: Implications of structural and immunological constraints for vaccine and drug development.Structural flexibility at a major conserved antibody target on hepatitis C virus E2 antigen.Prospects for prophylactic hepatitis C vaccines based on virus-like particlesNative Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG.Complete definition of immunological correlates of protection and clearance of hepatitis C virus infection: a relevant pending task for vaccine development.Challenges to the development of vaccines to hepatitis C virus that elicit neutralizing antibodies.Hepatitis C virus infection upregulates CD55 expression on the hepatocyte surface and promotes association with virus particles.Progress in the development of vaccines for hepatitis C virus infection.Amino acid residue-specific neutralization and nonneutralization of hepatitis C virus by monoclonal antibodies to the E2 protein.Immunization of human volunteers with hepatitis C virus envelope glycoproteins elicits antibodies that cross-neutralize heterologous virus strains.A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques.A comparison of immunogenicity of norovirus GII-4 virus-like particles and P-particles.Designing a B Cell-Based Vaccine against a Highly Variable Hepatitis C Virus.Hepatitis C virus E2 envelope glycoprotein induces an immunoregulatory phenotype in macrophages.The Neutralizing Face of Hepatitis C Virus E2 Envelope Glycoprotein.Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.Hepatitis C Vaccines, Antibodies, and T Cells.
P2860
Q26782040-9B7D81EE-4D24-4E00-9FC1-FEFDCEC6378DQ27027484-461EDB42-F02E-432E-8E9B-8B1102664357Q27333881-607382DD-66C0-4DE8-81B0-A92C68DA3E9DQ27677400-972A21E0-3403-422D-940B-4B7C91D5A1DAQ27684579-22EF1066-7453-4CD5-A05B-8B6D9BF44119Q28488268-DFBA8999-913B-4A51-B913-0723AFD954D6Q30374314-3AC6351C-8527-45AD-9172-E43B562E86D6Q33563569-4520CA66-EB06-4EDE-9C4C-5B88BF6C08A4Q33602744-A1586123-7C94-4426-A172-FF03E92FB60DQ33890011-AC3EE6DF-838A-4648-BE9A-2C39345496FAQ34009510-9C3C7C38-090F-471F-AF03-09CCD4703D55Q34262165-22B605AF-D588-42B4-93B8-4083A1D249C5Q34543833-76C72E90-D577-4AA6-8F3C-F592BF0596A6Q34693362-882690E0-ED77-4114-85E6-C576C9C3A7F8Q34781537-85894DAB-48FC-42B9-AAC3-48184846429EQ35669397-295FEF2E-2812-436E-A36F-9E8F1DA7F341Q35728873-1E5BCA64-4B8D-45B2-8BB1-47C67126AAA0Q35912053-BD28C61E-6A99-4A22-9C28-AA9ACAD7E77BQ35913863-A64332EE-0696-44D5-B835-387EA1798F0DQ36363203-A1DD3F96-2131-4950-A755-4EB44D547724Q36378193-78E43367-5E6D-4E1A-8603-0B30FD0030EAQ36827324-C2A2F555-EAD8-48E3-9675-4B7A616B8D87Q37181386-968BC405-7A5B-4339-9B3E-9EC77185D49DQ37354049-C9AB1712-16D8-47C0-AC99-A4847761893AQ37417839-C1096739-AA29-4A4F-A0EF-53F98F794252Q37505405-3033C736-2BFF-41C8-ABB8-7259071C7641Q37512845-31FDEF4F-0C76-42DA-B9EC-D62229099DC6Q38010203-7C4C34E3-F274-4536-B1BB-6715F200D7FCQ38234934-0030C8A1-7C14-4C0F-889B-940CEA28D0CEQ38315657-D5B7EAA9-8E9F-4022-8480-33DAAFCCBA8CQ38635596-90FA48E6-F904-45DF-9A8A-AC4EE3D67952Q41168118-3ACE212A-B84F-4E57-838F-67C3E452EBF4Q42951318-9EB12D0A-1C51-4E7C-9128-FF0F932126C4Q43039402-512BCDD2-1586-4D21-8A1F-0991DEAA9AA6Q45362011-638B5F4E-5AFF-48B2-9404-371B3C47F39BQ47548062-6CC9A2BB-09E1-4013-AE77-DCD1EA8B1447Q50005891-76C8B47F-E4CF-460E-8892-029553FDF7F9Q55299977-AFEAFA00-645C-4FEB-B01A-3F83825BDE07Q55385159-7F94630B-78E6-4CD4-98A2-D68DA97838AAQ55709137-9657E2B8-B48D-418B-97C6-E32EE3C3703A
P2860
Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Characterization of antibodies ...... virus envelope glycoproteins.
@ast
Characterization of antibodies ...... virus envelope glycoproteins.
@en
Characterization of antibodies ...... virus envelope glycoproteins.
@nl
type
label
Characterization of antibodies ...... virus envelope glycoproteins.
@ast
Characterization of antibodies ...... virus envelope glycoproteins.
@en
Characterization of antibodies ...... virus envelope glycoproteins.
@nl
prefLabel
Characterization of antibodies ...... virus envelope glycoproteins.
@ast
Characterization of antibodies ...... virus envelope glycoproteins.
@en
Characterization of antibodies ...... virus envelope glycoproteins.
@nl
P2093
P2860
P50
P356
P1476
Characterization of antibodies ...... C virus envelope glycoproteins
@en
P2093
Arnab Basu
Keith Meyer
Michael Houghton
Ranjit Ray
Sharon E Frey
Stephen Coates
P2860
P304
P356
10.1086/655902
P407
P577
2010-09-01T00:00:00Z